Servier (Tianjin) Pharmaceutical Co. LTD.

3 clinical trials · Sponsor

Record	Firm	Date
A Multicentre, Retrospective-prospective Real-world Study: to Evaluate the Effectiveness and Safety of Vorasidenib in Patients With Isocitrate Dehydrogenase IDH1/2 Mutant Grade 2 Astrocytoma or Oligodendroglioma (VICTORIA Study) (NCT06969352)	Servier (Tianjin) Pharmaceutical Co. LTD.	2025-09-02
A Multi-center, Single-arm, Prospective Non-interventional Study to Investigate the Safety Profiles and Effectiveness of Liposomal Irinotecan (ONIVYDE®) in Combination with 5-fluorouracil (5-FU) and Leucovorin (LV) in Chinese Patients with Metastatic Pancreatic Cancer As Approval Condition (SEOPAC) (NCT06688240)	Servier (Tianjin) Pharmaceutical Co. LTD.	2024-11-01

Every clearance here is in the API, with alerts when new ones post.